Functional and structural analysis of cytokine-selective IL6ST defects that cause recessive hyper-IgE syndrome.


Journal

The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002

Informations de publication

Date de publication:
08 2021
Historique:
received: 08 07 2020
revised: 24 01 2021
accepted: 12 02 2021
pubmed: 28 3 2021
medline: 21 10 2021
entrez: 27 3 2021
Statut: ppublish

Résumé

Biallelic variants in IL6ST, encoding GP130, cause a recessive form of hyper-IgE syndrome (HIES) characterized by high IgE level, eosinophilia, defective acute phase response, susceptibility to bacterial infections, and skeletal abnormalities due to cytokine-selective loss of function in GP130, with defective IL-6 and IL-11 and variable oncostatin M (OSM) and IL-27 levels but sparing leukemia inhibitory factor (LIF) signaling. Our aim was to understand the functional and structural impact of recessive HIES-associated IL6ST variants. We investigated a patient with HIES by using exome, genome, and RNA sequencing. Functional assays assessed IL-6, IL-11, IL-27, OSM, LIF, CT-1, CLC, and CNTF signaling. Molecular dynamics simulations and structural modeling of GP130 cytokine receptor complexes were performed. We identified a patient with compound heterozygous novel missense variants in IL6ST (p.Ala517Pro and the exon-skipping null variant p.Gly484_Pro518delinsArg). The p.Ala517Pro variant resulted in a more profound IL-6- and IL-11-dominated signaling defect than did the previously identified recessive HIES IL6ST variants p.Asn404Tyr and p.Pro498Leu. Molecular dynamics simulations suggested that the p.Ala517Pro and p.Asn404Tyr variants result in increased flexibility of the extracellular membrane-proximal domains of GP130. We propose a structural model that explains the cytokine selectivity of pathogenic IL6ST variants that result in recessive HIES. The variants destabilized the conformation of the hexameric cytokine receptor complexes, whereas the trimeric LIF-GP130-LIFR complex remained stable through an additional membrane-proximal interaction. Deletion of this membrane-proximal interaction site in GP130 consequently caused additional defective LIF signaling and Stüve-Wiedemann syndrome. Our data provide a structural basis to understand clinical phenotypes in patients with IL6ST variants.

Sections du résumé

BACKGROUND
Biallelic variants in IL6ST, encoding GP130, cause a recessive form of hyper-IgE syndrome (HIES) characterized by high IgE level, eosinophilia, defective acute phase response, susceptibility to bacterial infections, and skeletal abnormalities due to cytokine-selective loss of function in GP130, with defective IL-6 and IL-11 and variable oncostatin M (OSM) and IL-27 levels but sparing leukemia inhibitory factor (LIF) signaling.
OBJECTIVE
Our aim was to understand the functional and structural impact of recessive HIES-associated IL6ST variants.
METHODS
We investigated a patient with HIES by using exome, genome, and RNA sequencing. Functional assays assessed IL-6, IL-11, IL-27, OSM, LIF, CT-1, CLC, and CNTF signaling. Molecular dynamics simulations and structural modeling of GP130 cytokine receptor complexes were performed.
RESULTS
We identified a patient with compound heterozygous novel missense variants in IL6ST (p.Ala517Pro and the exon-skipping null variant p.Gly484_Pro518delinsArg). The p.Ala517Pro variant resulted in a more profound IL-6- and IL-11-dominated signaling defect than did the previously identified recessive HIES IL6ST variants p.Asn404Tyr and p.Pro498Leu. Molecular dynamics simulations suggested that the p.Ala517Pro and p.Asn404Tyr variants result in increased flexibility of the extracellular membrane-proximal domains of GP130. We propose a structural model that explains the cytokine selectivity of pathogenic IL6ST variants that result in recessive HIES. The variants destabilized the conformation of the hexameric cytokine receptor complexes, whereas the trimeric LIF-GP130-LIFR complex remained stable through an additional membrane-proximal interaction. Deletion of this membrane-proximal interaction site in GP130 consequently caused additional defective LIF signaling and Stüve-Wiedemann syndrome.
CONCLUSION
Our data provide a structural basis to understand clinical phenotypes in patients with IL6ST variants.

Identifiants

pubmed: 33771552
pii: S0091-6749(21)00471-1
doi: 10.1016/j.jaci.2021.02.044
pii:
doi:

Substances chimiques

Cytokines 0
IL6ST protein, human 0
Cytokine Receptor gp130 133483-10-0

Types de publication

Case Reports Clinical Trial Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

585-598

Subventions

Organisme : NHGRI NIH HHS
ID : U01 HG007708
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG010218
Pays : United States
Organisme : Department of Health
Pays : United Kingdom
Organisme : NHGRI NIH HHS
ID : U01 HG007530
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG007942
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG007943
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001085
Pays : United States

Informations de copyright

Copyright © 2021 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Auteurs

Yin-Huai Chen (YH)

Translational Gastroenterology Unit, University of Oxford, Oxford, United Kingdom.

Diane B Zastrow (DB)

Center for Undiagnosed Diseases, Stanford University, Stanford, Calif.

Riley D Metcalfe (RD)

Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, Australia.

Lisa Gartner (L)

Translational Gastroenterology Unit, University of Oxford, Oxford, United Kingdom.

Freia Krause (F)

Christian-Albrechts-University Kiel, Institute of Biochemistry, Kiel, Germany.

Craig J Morton (CJ)

Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, Australia.

Shruti Marwaha (S)

Center for Undiagnosed Diseases, Stanford University, Stanford, Calif.

Laure Fresard (L)

Center for Undiagnosed Diseases, Stanford University, Stanford, Calif; Department of Pathology, Stanford School of Medicine, Stanford, Calif.

Yong Huang (Y)

Center for Undiagnosed Diseases, Stanford University, Stanford, Calif.

Chunli Zhao (C)

Center for Undiagnosed Diseases, Stanford University, Stanford, Calif.

Colleen McCormack (C)

Center for Undiagnosed Diseases, Stanford University, Stanford, Calif.

David Bick (D)

Hudson Alpha Institute for Biotechnology, Huntsville, Ala.

Elizabeth A Worthey (EA)

Hudson Alpha Institute for Biotechnology, Huntsville, Ala.

Christine M Eng (CM)

Center for Undiagnosed Diseases, Stanford University, Stanford, Calif; Baylor College of Medicine, Houston, Tex.

Jessica Gold (J)

Department of Pediatrics, Stanford University School of Medicine, Stanford, Calif.
National Institutes of Health Undiagnosed Diseases Network, Common Fund, Office of the Director and the National Human Genome Research Institute, National Institutes of Health, Bethesda, Md.

Stephen B Montgomery (SB)

Center for Undiagnosed Diseases, Stanford University, Stanford, Calif; Department of Pathology, Stanford School of Medicine, Stanford, Calif; Department of Genetics, Stanford University School of Medicine, Stanford, Calif.

Paul G Fisher (PG)

Center for Undiagnosed Diseases, Stanford University, Stanford, Calif; Department of Neurology, Stanford University School of Medicine, Stanford University, Stanford, Calif.

Euan A Ashley (EA)

Center for Undiagnosed Diseases, Stanford University, Stanford, Calif; Department of Genetics, Stanford University School of Medicine, Stanford, Calif.

Matthew T Wheeler (MT)

Center for Undiagnosed Diseases, Stanford University, Stanford, Calif; Department of Medicine, Stanford School of Medicine, Stanford, Calif.

Michael W Parker (MW)

Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, Australia; St Vincent's Institute of Medical Research, Melbourne, Australia.

Veerabahu Shanmugasundaram (V)

Bristol-Myers Squibb, Cambridge, Mass.

Tracy L Putoczki (TL)

Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; Department of Medical Biology, The University of Melbourne, Melbourne, Australia.

Dirk Schmidt-Arras (D)

Christian-Albrechts-University Kiel, Institute of Biochemistry, Kiel, Germany.

Arian Laurence (A)

Translational Gastroenterology Unit, University of Oxford, Oxford, United Kingdom. Electronic address: arian.laurence@ndm.ox.ac.uk.

Jonathan A Bernstein (JA)

Center for Undiagnosed Diseases, Stanford University, Stanford, Calif; Department of Pediatrics, Stanford University School of Medicine, Stanford, Calif.

Michael D W Griffin (MDW)

Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, Australia.

Holm H Uhlig (HH)

Translational Gastroenterology Unit, University of Oxford, Oxford, United Kingdom; Department of Paediatrics, University of Oxford, Oxford, United Kingdom; Oxford National Institute for Health Research Biomedical Research Centre, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH